PPGN.SW PolyPeptide Group AG (SIX) down 8.82% pre-market 14 Mar 2026: watch CHF23.30 support

PPGN.SW stock opened the pre-market session down 8.82%, trading at CHF24.30 on 14 Mar 2026 after an opening print of CHF26.40. Volume is elevated at 218,822 shares versus an average of 66,222, signalling heavy selling ahead of the Swiss session on the SIX exchange. The one-day decline follows a recent slide from the 50-day average of CHF26.88 and pushes price close to the intraday low CHF23.30. We assess fundamentals, technicals and Meyka AI model forecasts to explain why PolyPeptide Group AG is a top loser in pre-market trade

PPGN.SW stock: session moves and market context

Pre-market action shows PPGN.SW stock down 8.82% to CHF24.30 on 14 Mar 2026. Open was CHF26.40, previous close CHF26.65, day low CHF23.30, day high CHF26.40. Trading volume is 218,822 versus an average of 66,222, a relative volume of 3.30, indicating outsized selling pressure in Switzerland on the SIX exchange.

PPGN.SW stock fundamentals and valuation

PolyPeptide Group AG reports EPS -0.94 and a trailing PE of -25.85, reflecting negative earnings. Market capitalization stands at CHF801,692,235.00 with 32,991,450.00 shares outstanding. Key ratios show price-to-sales 2.28, price-to-book 2.61, current ratio 1.74, and debt-to-equity 0.38, indicating moderate leverage versus healthcare peers.

PPGN.SW stock: technical picture and short-term levels

Technicals show RSI 55.14, MACD histogram 0.11, and ATR 1.27, pointing to mixed momentum but higher volatility. The 50-day average is CHF26.88 and the 200-day average is CHF24.68, placing price below the 50-day but near the 200-day. Immediate support sits at CHF23.30 and resistance at CHF26.40. On a break below CHF23.30, the next target is the year low CHF13.22.

PPGN.SW stock: growth, cash flow and risks

Revenue per share is CHF11.81 and operating cash flow per share is CHF2.34. Free cash flow per share is negative at CHF-0.92, and interest coverage is weak at 0.22, raising short-term funding risk. Inventory days are high at 172.77, creating working capital strain. These metrics increase execution risk for peptide contract manufacturing and generic product rollouts.

PPGN.SW stock: valuation grade and analyst view

Meyka AI rates PPGN.SW with a score out of 100: 69.42 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Third-party company rating dated 2026-03-13 shows a C- / Strong Sell stance on several DCF and profitability metrics, highlighting divergence between quantitative model and some fundamental scores.

PPGN.SW stock catalysts, news and outlook

Catalysts include upcoming earnings on 2026-08-13, contract wins, and clinical peptide program updates. The company website lists product and regulatory capabilities that can drive revenue Polypeptide Group website. Watch sector performance in Healthcare, where average P/E is 29.59 and net margin is 19.83%; PolyPeptide’s negative margins create downside sensitivity if peers outperform.

Final Thoughts

PPGN.SW stock is a pre-market top loser on 14 Mar 2026, down 8.82% to CHF24.30 with heavy volume of 218,822. Fundamentals show negative EPS -0.94 and weak free cash flow CHF-0.92 per share. Technicals place the stock below the 50-day average CHF26.88 and close to the 200-day average CHF24.68, making the CHF23.30 level a critical short-term support. Meyka AI’s forecast model projects a yearly price of CHF31.95, implying an upside of 31.48% versus today’s CHF24.30. Forecasts are model-based projections and not guarantees. Given a Meyka AI grade of 69.42 (B, HOLD) and mixed external ratings, we see a cautious trading opportunity: short-term momentum favors sellers while model-driven targets show material upside if execution improves. Track upcoming earnings, cash conversion cycle improvements, and contract announcements before increasing exposure. For more company details visit PPGN.SW on Meyka or the firm profile at PolyPeptide LinkedIn.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.